1. Home
  2. TV vs PHVS Comparison

TV vs PHVS Comparison

Compare TV & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grupo Televisa S.A.

TV

Grupo Televisa S.A.

HOLD

Current Price

$3.00

Market Cap

1.5B

Sector

Industrials

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$24.24

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TV
PHVS
Founded
1969
2015
Country
Mexico
Switzerland
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
1993
2021

Fundamental Metrics

Financial Performance
Metric
TV
PHVS
Price
$3.00
$24.24
Analyst Decision
Strong Buy
Buy
Analyst Count
4
9
Target Price
$4.93
$39.44
AVG Volume (30 Days)
1.4M
563.8K
Earning Date
10-23-2025
11-12-2025
Dividend Yield
2.70%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,246,959,081.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.55
$11.51
52 Week High
$3.10
$29.80

Technical Indicators

Market Signals
Indicator
TV
PHVS
Relative Strength Index (RSI) 65.67 47.59
Support Level $2.67 $23.15
Resistance Level $3.07 $29.80
Average True Range (ATR) 0.09 2.06
MACD 0.02 -0.37
Stochastic Oscillator 83.54 15.04

Price Performance

Historical Comparison
TV
PHVS

About TV Grupo Televisa S.A.

Televisa is one of the leading telecommunication firms in Mexico. Its cable arm, Izzi, holds networks that pass 20 million Mexican homes and provide broadband service to nearly 6 million customers. The firm is also one of the largest pay-television providers in Mexico, with 4 million customers. Televisa owns Sky Mexico, the country's only satellite-TV provider, serving about 5 million customers. After merging its traditional media business into Univision, Grupo Televisa owns a 43% stake in combined entity TelevisaUnivision. Grupo Televisa spun off several smaller businesses, including magazine publishing, three of Mexico's professional soccer teams, and Azteca Stadium in February 2024, under the name Ollamani.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: